NASDAQ:IMPL Impel Pharmaceuticals - IMPL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.59 +0.15 (+4.36%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.36▼$3.6050-Day Range$2.59▼$4.1052-Week Range$2.52▼$10.75Volume8,007 shsAverage Volume24,823 shsMarket Capitalization$85.23 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Impel Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside491.9% Upside$21.25 Price TargetShort InterestHealthy1.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.65) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector448th out of 1,055 stocksPharmaceutical Preparations Industry217th out of 519 stocks 3.3 Analyst's Opinion Consensus RatingImpel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.25, Impel Pharmaceuticals has a forecasted upside of 491.9% from its current price of $3.59.Amount of Analyst CoverageImpel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.63% of the float of Impel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverImpel Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Impel Pharmaceuticals has recently decreased by 38.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImpel Pharmaceuticals does not currently pay a dividend.Dividend GrowthImpel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMPL. Previous Next 2.5 News and Social Media Coverage News SentimentImpel Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Impel Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for IMPL on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Impel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Impel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.30% of the stock of Impel Pharmaceuticals is held by insiders.Percentage Held by Institutions63.92% of the stock of Impel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Impel Pharmaceuticals are expected to grow in the coming year, from ($4.65) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Impel Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Impel Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImpel Pharmaceuticals has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Impel Pharmaceuticals (NASDAQ:IMPL) StockImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.Read More Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comBrokers Offer Predictions for Impel Pharmaceuticals Inc.'s FY2027 Earnings (NASDAQ:IMPL)January 25, 2023 | americanbankingnews.comWedbush Analysts Decrease Earnings Estimates for Impel Pharmaceuticals Inc. (NASDAQ:IMPL)January 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 23, 2023 | americanbankingnews.comShort Interest in Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Declines By 6.2%November 14, 2022 | seekingalpha.comImpel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | nasdaq.comImpel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue EstimatesNovember 14, 2022 | finance.yahoo.comImpel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 14, 2022 | finance.yahoo.comInvestors in Impel Pharmaceuticals (NASDAQ:IMPL) have unfortunately lost 67% over the last yearJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 8, 2022 | finance.yahoo.comImpel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology DayNovember 8, 2022 | finance.yahoo.comImpel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022October 18, 2022 | seekingalpha.comIMPL Impel Pharmaceuticals Inc.October 18, 2022 | finance.yahoo.comImpel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Shift From Loss To ProfitOctober 2, 2022 | nasdaq.comImpel Pharmaceuticals Inc. (NASDAQ:IMPL) drops to US$116m and insiders who purchased earlier this year lose another US$59kSeptember 23, 2022 | finance.yahoo.comInsiders who bought this year lost US$49k as Impel Pharmaceuticals Inc. (NASDAQ:IMPL) sheds US$34m in valueSeptember 6, 2022 | finance.yahoo.comImpel Pharmaceuticals to Participate in Upcoming Investor Conferences in SeptemberAugust 15, 2022 | baystreet.caImpel Dips on Q2 NumbersAugust 15, 2022 | seekingalpha.comImpel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call TranscriptAugust 15, 2022 | nasdaq.comImpel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue EstimatesAugust 15, 2022 | msn.comImpel Pharmaceuticals: Q2 Earnings InsightsAugust 15, 2022 | finance.yahoo.comImpel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 9, 2022 | finance.yahoo.comHere's What Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Shareholder Ownership Structure Looks LikeAugust 8, 2022 | finance.yahoo.comImpel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022August 2, 2022 | finance.yahoo.comImpel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare ConferenceJuly 19, 2022 | msn.comImpel Commences Mid-Stage Autism Spectrum Disorder StudyJuly 19, 2022 | finance.yahoo.comImpel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)June 28, 2022 | seekingalpha.comImpel Pharmaceuticals: Under The Radar Despite Upside PotentialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Company Calendar Last Earnings11/14/2022Today1/28/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.25 High Stock Price Forecast$40.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+317.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,540,000.00 Net Margins-1,313.87% Pretax Margin-1,313.84% Return on Equity-701.26% Return on Assets-91.67% Debt Debt-to-Equity Ratio12.07 Current Ratio4.97 Quick Ratio4.54 Sales & Book Value Annual Sales$670,000.00 Price / Sales127.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book1.57Miscellaneous Outstanding Shares23,740,000Free Float22,243,000Market Cap$85.23 million OptionableNot Optionable Beta-0.62 Key ExecutivesMr. Adrian Adams (Age 71)Chairman & CEO Comp: $956.42kDr. John D. Hoekman Ph.D. (Age 41)Co-Founder and Chief Technology & Devel. Officer Dr. John H. Leaman M.D. (Age 49)Chief Financial & Bus. Officer Comp: $964.37kMr. Leonard S. Paolillo (Age 43)Chief Commercial Officer Comp: $496.7kMs. Jennifer L. BermanVP of MarketingMs. Patty BillingsleyVP of SalesMs. Sarah WilleVP of HRDr. Stephen Bevan Shrewsbury M.B. Ch.B. (Age 65)M.D., Chief Medical Officer Dr. Lynn C. Gold Ph.D. (Age 65)Sr. VP of Regulatory Mr. Scott Youmans (Age 55)Sr. VP of Technical Operations More ExecutivesKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBEnlivex TherapeuticsNASDAQ:ENLVMainz Biomed B.V.NASDAQ:MYNZAdageneNASDAQ:ADAGViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInsiders & InstitutionsMcdonald Partners LLCBought 11,700 shares on 1/18/2023Ownership: 0.049%BlackRock Inc.Bought 9,783 shares on 11/15/2022Ownership: 0.452%Citadel Advisors LLCBought 13,217 shares on 11/15/2022Ownership: 0.056%Ergoteles LLCSold 3,953 shares on 11/14/2022Ownership: 0.103%Tower Research Capital LLC TRC Bought 9,035 shares on 11/10/2022Ownership: 0.043%View All Institutional Transactions IMPL Stock - Frequently Asked Questions Should I buy or sell Impel Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impel Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMPL shares. View IMPL analyst ratings or view top-rated stocks. What is Impel Pharmaceuticals' stock price forecast for 2023? 2 equities research analysts have issued twelve-month price targets for Impel Pharmaceuticals' stock. Their IMPL share price forecasts range from $5.00 to $40.00. On average, they predict the company's share price to reach $21.25 in the next twelve months. This suggests a possible upside of 491.9% from the stock's current price. View analysts price targets for IMPL or view top-rated stocks among Wall Street analysts. How have IMPL shares performed in 2023? Impel Pharmaceuticals' stock was trading at $3.75 at the beginning of the year. Since then, IMPL stock has decreased by 4.3% and is now trading at $3.59. View the best growth stocks for 2023 here. When is Impel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our IMPL earnings forecast. How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings data on Monday, November, 14th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.44. The company earned $3.08 million during the quarter, compared to analyst estimates of $5.16 million. Impel Pharmaceuticals had a negative trailing twelve-month return on equity of 701.26% and a negative net margin of 1,313.87%. When did Impel Pharmaceuticals IPO? (IMPL) raised $80 million in an IPO on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO. What is Impel Pharmaceuticals' stock symbol? Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMPL." Who are Impel Pharmaceuticals' major shareholders? Impel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mcdonald Partners LLC (0.05%). Insiders that own company stock include Adrian Adams, Global Strategic Fund I Venbio, Timothy S Nelson and Vivo Capital Viii, Llc. View institutional ownership trends. How do I buy shares of Impel Pharmaceuticals? Shares of IMPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Impel Pharmaceuticals' stock price today? One share of IMPL stock can currently be purchased for approximately $3.59. How much money does Impel Pharmaceuticals make? Impel Pharmaceuticals (NASDAQ:IMPL) has a market capitalization of $85.23 million and generates $670,000.00 in revenue each year. The company earns $-76,540,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. How many employees does Impel Pharmaceuticals have? The company employs 129 workers across the globe. How can I contact Impel Pharmaceuticals? The official website for the company is www.Impelnp.com. The company can be reached via phone at 206-568-1466. This page (NASDAQ:IMPL) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.